Abstracts this author is presenting:
-
A phase 1b/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC)
—
Lunch, Poster Viewing, Exhibition & COSA Group Meetings
-
A Phase 1 (Ph1) Study of the OX40 Agonist, BGB-A445, With or Without Tislelizumab, an Anti-PD-1 Monoclonal Antibody (mAb), in Patients With Advanced Solid Tumors
—
Lunch, Poster Viewing, Exhibition & COSA Group Meetings
-
A 10 year experience of cardiac toxicity in patients receiving HER2 directed therapies at a tertiary Australian centre
—
Lunch, Poster Viewing, Exhibition & COSA Group Meetings